We are dedicated to eliminating bacterial infections such as invasive pneumococcal disease, Group A Strep, periodontitis and Shigella to protect every child born and every adult at risk across the globe.

Despite widespread vaccination with current pneumococcal conjugate vaccines (PCVs), there is an abundance of non-vaccine strains of the Streptococcus pneumoniae bacteria causing significant morbidity and mortality. This underscores the importance of advancing VAX-24, our lead 24-valent PCV candidate, which is the broadest-spectrum PCV in U.S. clinics today. Upon achieving clinical proof-of-concept, VAX-24 was granted FDA Breakthrough Therapy designation for the prevention of invasive pneumococcal disease in adults.

We strive to overcome the limitations of conventional, cell-based vaccine approaches using advanced chemistry and modern synthetic techniques – including our XpressCF™ cell-free protein synthesis platform – to produce broad-spectrum vaccines that are uniquely capable of breaking down bacteria’s complex defense mechanisms while preserving immunogenicity.

Our PCV franchise is intended to improve upon existing pneumococcal vaccines by covering a significant portion of the invasive pneumococcal disease currently in circulation that is associated with high case-fatality rates, antibiotic resistance and meningitis. Following VAX-24, we are developing VAX-31, a 31-valent PCV candidate. Additional vaccine candidates in preclinical development target Group A Strep, periodontitis and Shigella.

Looking for higher aspirations to ignite your mind and inspire your heart? Then join a team that brings grit and grace to the challenge of protecting every human from the consequences of endemic bacterial infections.

Vaxcyte is a clinical-stage vaccine innovation company based in San Carlos, California with a unique ability to rapidly engineer, optimize and manufacture superior, high-fidelity vaccines at scale. We do this by re-engineering how highly complex vaccines are made, using advanced chemistry and modern synthetic techniques – including the XpressCF™ cell-free protein synthesis platform – to create difficult-to-make proteins that deliver enhanced immunological benefits.

Our lead clinical candidate, VAX-24, a 24-valent pneumococcal conjugate vaccine (PCV), was granted FDA Breakthrough Therapy designation for the prevention of invasive pneumococcal disease in adults. We are pursuing a clear strategy for our PCV franchise, which leverages a known regulatory pathway established by already approved PCVs. We are preparing to deliver PCVs at a global scale upon regulatory approval through a strategic supply relationship with Lonza, one of the world’s leading contract manufacturers of complex biologics.

In addition, our pipeline includes VAX-31, an even broader-spectrum PCV candidate, and other preclinical programs targeting Group A Strep, periodontitis and Shigella.

At Vaxcyte, we are driven to protect humankind by eliminating invasive bacterial infections that have serious and costly health consequences when left unchecked. Addressing pneumococcal disease, Group A Strep, periodontitis and Shigella are just the beginning. Our path to success is clear and well-defined, and Vaxcyte is set up to go the distance.